Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 593

1.

Overexpression of CYR61/CCN1 in the multiple myeloma microenvironment is associated with superior survival and prevention of bone disease.

Johnson SK, Stewart JP, Bam R, Qu P, Barlogie B, van Rhee F, Shaughnessy JD Jr, Epstein J, Yaccoby S.

Blood. 2014 Jul 24. pii: blood-2014-02-555813. [Epub ahead of print]

PMID:
25061178
[PubMed - as supplied by publisher]
2.

Treatment recommendations for patients with Waldenström's Macroglobulinemia (WM) and related disorders: consensus from the Seventh International Workshop on WM.

Dimopoulos M, Kastritis E, Owen RG, Kyle RA, Landgren O, Morra E, Leleu X, García-Sanz R, Munshi N, Anderson KC, Terpos E, Ghobrial IM, Morel P, Maloney D, Rummel M, Leblond V, Advani RH, Gertz MA, Kyriakou C, Thomas SK, Barlogie B, Gregory SA, Kimby E, Merlini G, Treon SP.

Blood. 2014 Jul 15. pii: blood-2014-03-565135. [Epub ahead of print]

PMID:
25027391
[PubMed - as supplied by publisher]
3.

Artesunate overcomes drug resistance in multiple myeloma by inducing mitochondrial stress and non-caspase apoptosis.

Papanikolaou X, Johnson S, Garg T, Tian E, Tytarenko R, Zhang Q, Stein C, Barlogie B, Epstein J, Heuck C.

Oncotarget. 2014 Jun 30;5(12):4118-28.

PMID:
24948357
[PubMed - in process]
Free Article
4.

Hepatitis B reactivation in patients with multiple myeloma and isolated positive hepatitis B core antibody: a call for greater cognizance.

Yang JD, Girotra M, Restrepo A, Waheed S, Barlogie B, Duarte-Rojo A.

Ann Hepatol. 2014 Jul-Aug;13(4):461-5.

PMID:
24927619
[PubMed - in process]
5.

A phase II trial of BAY 43-9006 (sorafenib) (NSC-724772) in patients with relapsing and resistant multiple myeloma: SWOG S0434.

Srkalovic G, Hussein MA, Hoering A, Zonder JA, Popplewell LL, Trivedi H, Mazzoni S, Sexton R, Orlowski RZ, Barlogie B.

Cancer Med. 2014 Jun 10. doi: 10.1002/cam4.276. [Epub ahead of print]

PMID:
24913924
[PubMed - as supplied by publisher]
6.

The future of autologous stem cell transplantation in myeloma.

van Rhee F, Giralt S, Barlogie B.

Blood. 2014 Jul 17;124(3):328-333. Epub 2014 Jun 3. Review.

PMID:
24894774
[PubMed - as supplied by publisher]
7.

Translating a gene expression signature for multiple myeloma prognosis into a robust high-throughput assay for clinical use.

van Laar R, Flinchum R, Brown N, Ramsey J, Riccitelli S, Heuck C, Barlogie B, Shaughnessy JD Jr.

BMC Med Genomics. 2014 May 17;7:25. doi: 10.1186/1755-8794-7-25.

PMID:
24885236
[PubMed - in process]
Free PMC Article
8.

Muscular Relapse in a Patient With Multiple Myeloma.

Waheed S, Zhu H, Waheed MA, Kumar M, Barlogie B.

J Clin Oncol. 2014 Apr 28. [Epub ahead of print] No abstract available.

PMID:
24778395
[PubMed - as supplied by publisher]
9.

Strange bedfellows: mitotically active chronic myeloid leukemia in molecular complete remission, detected in focal lesion of myeloma.

Guru Murthy GS, Sawyer J, Alapat D, Samant R, Barlogie B.

Clin Lymphoma Myeloma Leuk. 2014 Aug;14(4):e127-9. doi: 10.1016/j.clml.2014.02.008. Epub 2014 Feb 28. No abstract available.

PMID:
24685577
[PubMed - in process]
10.

In multiple myeloma, 14q32 translocations are nonrandom chromosomal fusions driving high expression levels of the respective partner genes.

Tian E, Sawyer JR, Heuck CJ, Zhang Q, van Rhee F, Barlogie B, Epstein J.

Genes Chromosomes Cancer. 2014 Jul;53(7):549-57. doi: 10.1002/gcc.22165. Epub 2014 Mar 17.

PMID:
24638926
[PubMed - in process]
11.

Second primary malignancies with lenalidomide therapy for newly diagnosed myeloma: a meta-analysis of individual patient data.

Palumbo A, Bringhen S, Kumar SK, Lupparelli G, Usmani S, Waage A, Larocca A, van der Holt B, Musto P, Offidani M, Petrucci MT, Evangelista A, Zweegman S, Nooka AK, Spencer A, Dimopoulos MA, Hajek R, Cavo M, Richardson P, Lonial S, Ciccone G, Boccadoro M, Anderson K, Barlogie B, Sonneveld P, McCarthy PL.

Lancet Oncol. 2014 Mar;15(3):333-42. doi: 10.1016/S1470-2045(13)70609-0. Epub 2014 Feb 11.

PMID:
24525202
[PubMed - indexed for MEDLINE]
12.

A compound T60A and V122I heterozygosity in the transthyretin gene causing early onset severe cardiac amyloidosis.

Liu YC, Reddi HV, Waheed S, Alapat D, Highsmith WE, Edmondson RD, Barlogie B, van Rhee F.

Amyloid. 2014 Jun;21(2):134-5. doi: 10.3109/13506129.2014.883373. Epub 2014 Feb 11. No abstract available.

PMID:
24517438
[PubMed - in process]
13.

Jumping translocations of 1q12 in multiple myeloma: a novel mechanism for deletion of 17p in cytogenetically defined high-risk disease.

Sawyer JR, Tian E, Heuck CJ, Epstein J, Johann DJ, Swanson CM, Lukacs JL, Johnson M, Binz R, Boast A, Sammartino G, Usmani S, Zangari M, Waheed S, van Rhee F, Barlogie B.

Blood. 2014 Apr 17;123(16):2504-12. doi: 10.1182/blood-2013-12-546077. Epub 2014 Feb 4.

PMID:
24497533
[PubMed - indexed for MEDLINE]
14.

Serial exome analysis of disease progression in premalignant gammopathies.

Zhao S, Choi M, Heuck C, Mane S, Barlogie B, Lifton RP, Dhodapkar MV.

Leukemia. 2014 Jul;28(7):1548-52. doi: 10.1038/leu.2014.59. Epub 2014 Feb 5. No abstract available.

PMID:
24496302
[PubMed - in process]
15.

Can autologous bone marrow transplantation improve systolic function in patients with multiple myeloma related cardiac amyloidosis?

Raina S, Pant S, Vallurupalli S, Jambhekar K, Pandey T, Grazziutti M, Barlogie B, Dai Y, Deshmukh A, Mehta JL.

Int J Cardiol. 2014 Mar 1;172(1):265-6. doi: 10.1016/j.ijcard.2013.12.249. Epub 2014 Jan 10. No abstract available.

PMID:
24456883
[PubMed - in process]
16.

Patterns of central nervous system involvement in relapsed and refractory multiple myeloma.

Abdallah AO, Atrash S, Shahid Z, Jameel M, Grazziutti M, Apewokin S, Kumar NS, Restrepo A, Waheed S, Van Rhee F, Heuck CJ, Johann D Jr, Barlogie B, Usmani SZ.

Clin Lymphoma Myeloma Leuk. 2014 Jun;14(3):211-4. doi: 10.1016/j.clml.2013.11.004. Epub 2013 Nov 16.

PMID:
24373936
[PubMed - in process]
17.

Analysis of CD34+ cell collection using two mobilization regimens for newly diagnosed multiple myeloma patients reveals the separate impact of mobilization and collection variables.

Abuabdou A, Rosenbaum ER, Usmani SZ, Barlogie B, Cottler-Fox M.

J Clin Apher. 2013 Dec 18. doi: 10.1002/jca.21313. [Epub ahead of print]

PMID:
24347510
[PubMed - as supplied by publisher]
18.

Reply to "Metronomic chemotherapy beyond misconceptions"--Haematologica 2013;98(11):e145.

Papanikolaou X, Heuck CJ, Barlogie B.

Haematologica. 2013 Nov;98(11):e149-50. doi: 10.3324/haematol.2013.098939. No abstract available.

PMID:
24186320
[PubMed - indexed for MEDLINE]
Free PMC Article
19.

Clinical, genomic, and imaging predictors of myeloma progression from asymptomatic monoclonal gammopathies (SWOG S0120).

Dhodapkar MV, Sexton R, Waheed S, Usmani S, Papanikolaou X, Nair B, Petty N, Shaughnessy JD Jr, Hoering A, Crowley J, Orlowski RZ, Barlogie B.

Blood. 2014 Jan 2;123(1):78-85. doi: 10.1182/blood-2013-07-515239. Epub 2013 Oct 21.

PMID:
24144643
[PubMed - indexed for MEDLINE]
20.

The clinical significance of cereblon expression in multiple myeloma.

Schuster SR, Kortuem KM, Zhu YX, Braggio E, Shi CX, Bruins LA, Schmidt JE, Ahmann G, Kumar S, Rajkumar SV, Mikhael J, Laplant B, Champion MD, Laumann K, Barlogie B, Fonseca R, Bergsagel PL, Lacy M, Stewart AK.

Leuk Res. 2014 Jan;38(1):23-8. doi: 10.1016/j.leukres.2013.08.015. Epub 2013 Sep 5.

PMID:
24129344
[PubMed - indexed for MEDLINE]
Free PMC Article

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Loading ...
Write to the Help Desk